Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tammuella Chrisentery-Singleton"'
Autor:
Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young
Publikováno v:
Blood. 140:8485-8488
Autor:
Tammuella Chrisentery-Singleton, Lisa N Boggio, Manuel Carcao, Sami Ibrahimi, Osman Khan, Arash Mahajerin, Anita Rajasekhar, Vivek Sharma, MacGregor Steele, Marcela Torres, Shannon L Carpenter
Publikováno v:
Blood. 140:5644-5646
Autor:
Tammuella Chrisentery-Singleton, Lauren E. Amos, Daniel Bonzo, Miguel Escobar, Adam Giermasz, Emmanuelle Lagrue, Christine Knoll, Sonia Nasr, Michael Recht, Spencer Sullivan, Doris V. Quon, Mark T. Reding
Publikováno v:
Blood. 140:11360-11361
Autor:
Steven W. Pipe, Cédric Hermans, Meera Chitlur, Manuel Carcao, Giancarlo Castaman, Joanna A. Davis, Jonathan Ducore, Amy L. Dunn, Miguel Escobar, Janna Journeycake, Osman Khan, Johnny Mahlangu, Shannon L. Meeks, Ismail Haroon Mitha, Claude Négrier, Ulrike Nowak‐Göttl, Michael Recht, Tammuella Chrisentery‐Singleton, Oleksandra Stasyshyn, Kateryna V. Vilchevska, Laura Villarreal Martinez, Michael Wang, Jerzy Windyga, Guy Young, W. Allan Alexander, Daniel Bonzo, Christopher Macie, Ian S. Mitchell, Evelyne Sauty, Thomas A. Wilkinson, Amy D. Shapiro
Publikováno v:
Haemophilia, Vol. 28, no. 4, p. 548-556 (2022)
INTRODUCTION: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older. AIM: To p
Publikováno v:
Hematology in the Adolescent Female ISBN: 9783030484453
Thrombotic microangiopathies (TMAs) are life-threatening hematologic disorders that share signs and symptoms present in other hematologic disorders, menorrhagia, and pregnancy. For clinicians caring for adolescent females, it is imperative to keep th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1838a604fc5f986c968473389b203ab5
https://doi.org/10.1007/978-3-030-48446-0_25
https://doi.org/10.1007/978-3-030-48446-0_25
Autor:
Tammuella Chrisentery-Singleton, Nikki Hirsh, Michael U. Callaghan, Miguel A. Escobar, W. Allan Alexander, Adam Giermasz, Daniel Bonzo, Sonia Nasr, Michael Recht, Doris Quon, Janna M. Journeycake, Ahmad Al-Sabbagh
Publikováno v:
Blood. 138:3201-3201
Background: A new recombinant activated factor VII, eptacog beta (SEVENFACT®, rFVIIa-jncw) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of bleeding events (BEs) in individuals >12 years of age with hemophilia A
Autor:
Michael Recht, Tammuella Chrisentery-Singleton, Vidhi Desai, Carol Fedor, Michael Wang, Annette von Drygalski, Robert F. Sidinio, Ellis J. Neufeld, Leslie Raffini, Birju Patel, Janna M. Journeycake, Xiang Zhang, Dunlei Cheng, Nikki Hirsh
Publikováno v:
Blood. 138:1039-1039
Introduction: The approval of extended half-life recombinant factor IX (rFIX) replacement products has expanded the range of therapeutic options available for the treatment of hemophilia B. Compared with standard half-life FIX, these products allow f
Autor:
Tammuella Chrisentery-Singleton, Ian S. Mitchell, Jonathan M. Ducore, Amy D. Shapiro, W. Allan Alexander, Oleksandra Stasyshyn, Manuel Carcao, Michael Recht, Amy L. Dunn, Jerzy Windyga, Ulrike Nowak-Göttl, Christopher Macie, Cédric Hermans, Ismail Haroon Mitha, Osman Khan, Laura Villarreal Martinez, Daniel Bonzo, Thomas A. Wilkinson, Janna M. Journeycake, Kateryna V. Vilchevska, Giancarlo Castaman, Joanna A. Davis, Shannon L. Meeks, Steven W. Pipe, Miguel A. Escobar, Guy Young, Michael Wang, Claude Negrier, Johnny Mahlangu, Ahmad Al-Sabbagh
Publikováno v:
Blood. 138:3195-3195
Introduction Following treatment with a bypassing agent, parents or caregivers often face difficulties in determining bleeding episode (BE) resolution in children with hemophilia A or B and inhibitors (CwHABI), potentially contributing to a longer tr